Skeletal muscle glucose uptake in patients with chronic myeloid leukemia on tyrosine kinase inhibitor therapy

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON29160

Enrollment

Registered

2019-11-21

Start date

2019-11-25

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

CML

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: Age: =18 years Fasting glucose level: = 6,0 mmol/l ? Specifically for CML patients: - Nilotinib treatment for at least 6 months prior to study inclusion OR - Imatinib treatment for at least 6 months prior to study inclusion

Exclusion criteria

Exclusion criteria: Contra-indication to exercise testing according to the ACC/AHA guidelines Incapable to provide informed consent ? Specifically for subgroup op participants undergoing [18F]FDG PET/CT scanning: - Renal dysfunction with MDRD <60 - Known prior allergic reaction to [18F]FDG

Design outcomes

Primary

Measure	Time frame
Differences in area under the curve (AUC) of glucose disappearance upon a single glucose bolus after an exercise bout.	—

Secondary

Measure	Time frame
Standard uptake value (SUV) of [18F]FDG as determined on PET/CT images.	—

Contacts

Public ContactLando Janssen

Radboudumc

Lando.Janssen@radboudumc.nl+31243614468

Outcome results